Editorial theme │ Understanding MDS classification and stratification systems: WHO and ICC

Here, we summarize the key points comparing classification systems in MDS—WHO and ICC—focusing on their pros...

Allo-HSCT in patients with high-risk MDS: Analysis from the BMT CTN 1102 trial

We summarize a genetic analysis from the BMT CTN 1102 trial that assessed the impact of the presence of high-risk...

Ivosidenib granted FDA approval for the treatment of patients with R/R IDH1-mutated MDS

On October 24, 2023, the U.S. FDA approved ivosidenib, an IDH1 inhibitor, for the treatment of adult patients...

FDA grants priority review and accepts supplemental new drug application for oral ivosidenib for the treatment of patients with IDH1-mutated R/R MDS

On August 15, 2023, the FDA accepted a supplemental...

EBMT 2023

Catch up with our live Twitter coverage from the EBMT Meeting, 2023.

Addition of gemtuzumab ozogamicin to induction chemotherapy

We summarize several presentations from ASH 2022 on the impact of gemtuzumab ozogamicin plus chemotherapy and fractionated versus single...

Novel treatment strategies in patients with high-risk and low-risk MDS

We summarize key updates from ASH 2022 on the promising outcomes of sabatolimab in high-risk MDS patients, as well as imetelstat...

Real-world validation of the IPSS-M risk stratification model for MDS and comparison to IPSS-R

The MDS Hub summarizes several presentations from ASH 2022 discussing the implementation of IPSS-M and...

Is there confusion between WHO and IPSS-M classifications of MDS?

During the 64th ASH Annual Meeting and Exposition, the MDS Hub was pleased to speak to Theo de Witte, Radboud University Medical...